Development of an ELISA based bridging assay as a surrogate measure of ADCC

Journal of Immunological Methods

Volumn 385, Issue 1-2, 2012, Pages 45-50

  Miller, Aaron S ^a   Tejada, Max L ^a   Gazzano Santoro, Hélène ^a  

^a GENENTECH INC   (United States)

Author keywords

ADCC; Bridging; ELISA; Surrogate

Indexed keywords

CD20 ANTIBODY; CD20 ANTIGEN;

ANALYTIC METHOD; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY REACTION; ARTICLE; ASSAY; CYTOLYSIS; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ENZYME-LINKED IMMUNOSORBENT ASSAY; FUCOSE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; KINETICS; LEUKOCYTES, MONONUCLEAR; PROTEIN BINDING; RECEPTORS, IGG; REPRODUCIBILITY OF RESULTS;

EID: 84866517109     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.08.004     Document Type: Article

References (21)

1. Alter G., Malenfant J.M., Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 2004, 294:15.
2. Bowles J.A., Weiner G.J. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J. Immunol. Methods 2005, 304:88.
3. Bryceson Y.T., March M.E., Ljunggren H.G., Long E.O. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol. Rev. 2006, 214:73.
4. Chan A.C., Carter P.J. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 2010, 10:301.
5. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 2000, 6:443.
6. Daeron M. Fc receptor biology. Annu. Rev. Immunol. 1997, 15:203.
7. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., Watier H., Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004, 64:4664.
8. Finney D.J. Statistical method in biological assay 1978, C. Griffin, London.
9. Gessner J.E., Heiken H., Tamm A., Schmidt R.E. The IgG Fc receptor family. Ann. Hematol. 1998, 76:231.
10. Imai-Nishiya H., Mori K., Inoue M., Wakitani M., Iida S., Shitara K., Satoh M. Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC. BMC Biotechnol. 2007, 7:84.
11. Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., Chan C., Chung H.S., Eivazi A., Yoder S.C., Vielmetter J., Carmichael D.F., Hayes R.J., Dahiyat B.I. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4005.
12. Liu X.Y., Pop L.M., Vitetta E.S. Engineering therapeutic monoclonal antibodies. Immunol. Rev. 2008, 222:9.
13. Ljunggren K., Fenyo E.M., Biberfeld G., Jondal M. Detection of antibodies which mediate human immunodeficiency virus-specific cellular cytotoxicity (ADCC) in vitro. J. Immunol. Methods 1987, 104:7.
14. Ma S., Lau W., Keck R.G., Briggs J.B., Jones A.J., Moorhouse K., Nashabeh W. Capillary electrophoresis of carbohydrates derivatized with fluorophoric compounds. Methods Mol. Biol. 2005, 308:397.
15. Nelson D.L., Kurman C.C., Serbousek D.E. 51Cr release assay of antibody-dependent cell-mediated cytotoxicity (ADCC). Curr. Protoc. Immunol. 2001, (Chapter 7, Unit 7 27).
16. Raju T.S. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol. 2008, 20:471.
17. Schnueriger A., Grau R., Sondermann P., Schreitmueller T., Marti S., Zocher M. Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies. Mol. Immunol. 2011, 48:1512.
18. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., Presta L.G. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 2001, 276:6591.
19. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H., Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 2002, 277:26733.
20. Wright A., Morrison S.L. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol. 1997, 15:26.
21. Yeh C. Statistics in the pharmaceutical industry 1994, M. Dekker, New York.